The global Systemic Sclerosis Drug market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Systemic Sclerosis Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Systemic Sclerosis Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Systemic Sclerosis Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key manufacturers of Systemic Sclerosis Drug include Allergan Plc, Angion Biomedica Corp., arGentis Pharmaceuticals, LLC, Bayer AG, BioLineRx, Ltd., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company and Corbus pharmaceuticals, Inc., etc. In 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes:
This report presents an overview of global market for Systemic Sclerosis Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Systemic Sclerosis Drug, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Systemic Sclerosis Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Systemic Sclerosis Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Systemic Sclerosis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Systemic Sclerosis Drug sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Allergan Plc, Angion Biomedica Corp., arGentis Pharmaceuticals, LLC, Bayer AG, BioLineRx, Ltd., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company and Corbus pharmaceuticals, Inc., etc.
By Company
Allergan Plc
Angion Biomedica Corp.
arGentis Pharmaceuticals, LLC
Bayer AG
BioLineRx, Ltd.
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Corbus pharmaceuticals, Inc.
CSL Limited
Daval International Limited
Digna Biotech, S.L.
F. Hoffmann-La Roche Ltd.
Fibrocell Science, Inc.
GenKyoTex S.A.
GlaxoSmithKline Plc
Segment by Type
ARG-201
Belimumab
BL-1110
BOT-191
C-82
Others
Segment by Application
Hospital
Clinic
ASCs
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Systemic Sclerosis Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Systemic Sclerosis Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Systemic Sclerosis Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Systemic Sclerosis Drug Product Introduction
1.2 Market by Type
1.2.1 Global Systemic Sclerosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 ARG-201
1.2.3 Belimumab
1.2.4 BL-1110
1.2.5 BOT-191
1.2.6 C-82
1.2.7 Others
1.3 Market by Application
1.3.1 Global Systemic Sclerosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 ASCs
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Systemic Sclerosis Drug Sales Estimates and Forecasts 2018-2029
2.2 Global Systemic Sclerosis Drug Revenue by Region
2.2.1 Global Systemic Sclerosis Drug Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Systemic Sclerosis Drug Revenue by Region (2018-2023)
2.2.3 Global Systemic Sclerosis Drug Revenue by Region (2024-2029)
2.2.4 Global Systemic Sclerosis Drug Revenue Market Share by Region (2018-2029)
2.3 Global Systemic Sclerosis Drug Sales Estimates and Forecasts 2018-2029
2.4 Global Systemic Sclerosis Drug Sales by Region
2.4.1 Global Systemic Sclerosis Drug Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Systemic Sclerosis Drug Sales by Region (2018-2023)
2.4.3 Global Systemic Sclerosis Drug Sales by Region (2024-2029)
2.4.4 Global Systemic Sclerosis Drug Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Systemic Sclerosis Drug Sales by Manufacturers
3.1.1 Global Systemic Sclerosis Drug Sales by Manufacturers (2018-2023)
3.1.2 Global Systemic Sclerosis Drug Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Systemic Sclerosis Drug in 2022
3.2 Global Systemic Sclerosis Drug Revenue by Manufacturers
3.2.1 Global Systemic Sclerosis Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Systemic Sclerosis Drug Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Systemic Sclerosis Drug Revenue in 2022
3.3 Global Key Players of Systemic Sclerosis Drug, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Systemic Sclerosis Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Systemic Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Systemic Sclerosis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Systemic Sclerosis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Systemic Sclerosis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Systemic Sclerosis Drug Sales by Type
4.1.1 Global Systemic Sclerosis Drug Historical Sales by Type (2018-2023)
4.1.2 Global Systemic Sclerosis Drug Forecasted Sales by Type (2024-2029)
4.1.3 Global Systemic Sclerosis Drug Sales Market Share by Type (2018-2029)
4.2 Global Systemic Sclerosis Drug Revenue by Type
4.2.1 Global Systemic Sclerosis Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Systemic Sclerosis Drug Forecasted Revenue by Type (2024-2029)
4.2.3 Global Systemic Sclerosis Drug Revenue Market Share by Type (2018-2029)
4.3 Global Systemic Sclerosis Drug Price by Type
4.3.1 Global Systemic Sclerosis Drug Price by Type (2018-2023)
4.3.2 Global Systemic Sclerosis Drug Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Systemic Sclerosis Drug Sales by Application
5.1.1 Global Systemic Sclerosis Drug Historical Sales by Application (2018-2023)
5.1.2 Global Systemic Sclerosis Drug Forecasted Sales by Application (2024-2029)
5.1.3 Global Systemic Sclerosis Drug Sales Market Share by Application (2018-2029)
5.2 Global Systemic Sclerosis Drug Revenue by Application
5.2.1 Global Systemic Sclerosis Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Systemic Sclerosis Drug Forecasted Revenue by Application (2024-2029)
5.2.3 Global Systemic Sclerosis Drug Revenue Market Share by Application (2018-2029)
5.3 Global Systemic Sclerosis Drug Price by Application
5.3.1 Global Systemic Sclerosis Drug Price by Application (2018-2023)
5.3.2 Global Systemic Sclerosis Drug Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Systemic Sclerosis Drug Market Size by Type
6.1.1 US & Canada Systemic Sclerosis Drug Sales by Type (2018-2029)
6.1.2 US & Canada Systemic Sclerosis Drug Revenue by Type (2018-2029)
6.2 US & Canada Systemic Sclerosis Drug Market Size by Application
6.2.1 US & Canada Systemic Sclerosis Drug Sales by Application (2018-2029)
6.2.2 US & Canada Systemic Sclerosis Drug Revenue by Application (2018-2029)
6.3 US & Canada Systemic Sclerosis Drug Market Size by Country
6.3.1 US & Canada Systemic Sclerosis Drug Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Systemic Sclerosis Drug Sales by Country (2018-2029)
6.3.3 US & Canada Systemic Sclerosis Drug Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Systemic Sclerosis Drug Market Size by Type
7.1.1 Europe Systemic Sclerosis Drug Sales by Type (2018-2029)
7.1.2 Europe Systemic Sclerosis Drug Revenue by Type (2018-2029)
7.2 Europe Systemic Sclerosis Drug Market Size by Application
7.2.1 Europe Systemic Sclerosis Drug Sales by Application (2018-2029)
7.2.2 Europe Systemic Sclerosis Drug Revenue by Application (2018-2029)
7.3 Europe Systemic Sclerosis Drug Market Size by Country
7.3.1 Europe Systemic Sclerosis Drug Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Systemic Sclerosis Drug Sales by Country (2018-2029)
7.3.3 Europe Systemic Sclerosis Drug Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Systemic Sclerosis Drug Market Size
8.1.1 China Systemic Sclerosis Drug Sales (2018-2029)
8.1.2 China Systemic Sclerosis Drug Revenue (2018-2029)
8.2 China Systemic Sclerosis Drug Market Size by Application
8.2.1 China Systemic Sclerosis Drug Sales by Application (2018-2029)
8.2.2 China Systemic Sclerosis Drug Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Systemic Sclerosis Drug Market Size by Type
9.1.1 Asia Systemic Sclerosis Drug Sales by Type (2018-2029)
9.1.2 Asia Systemic Sclerosis Drug Revenue by Type (2018-2029)
9.2 Asia Systemic Sclerosis Drug Market Size by Application
9.2.1 Asia Systemic Sclerosis Drug Sales by Application (2018-2029)
9.2.2 Asia Systemic Sclerosis Drug Revenue by Application (2018-2029)
9.3 Asia Systemic Sclerosis Drug Sales by Region
9.3.1 Asia Systemic Sclerosis Drug Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Systemic Sclerosis Drug Revenue by Region (2018-2029)
9.3.3 Asia Systemic Sclerosis Drug Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Systemic Sclerosis Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Systemic Sclerosis Drug Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Systemic Sclerosis Drug Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Systemic Sclerosis Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Systemic Sclerosis Drug Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Systemic Sclerosis Drug Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Systemic Sclerosis Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Systemic Sclerosis Drug Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Systemic Sclerosis Drug Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Systemic Sclerosis Drug Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Allergan Plc
11.1.1 Allergan Plc Company Information
11.1.2 Allergan Plc Overview
11.1.3 Allergan Plc Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Allergan Plc Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Allergan Plc Recent Developments
11.2 Angion Biomedica Corp.
11.2.1 Angion Biomedica Corp. Company Information
11.2.2 Angion Biomedica Corp. Overview
11.2.3 Angion Biomedica Corp. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Angion Biomedica Corp. Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Angion Biomedica Corp. Recent Developments
11.3 arGentis Pharmaceuticals, LLC
11.3.1 arGentis Pharmaceuticals, LLC Company Information
11.3.2 arGentis Pharmaceuticals, LLC Overview
11.3.3 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 arGentis Pharmaceuticals, LLC Recent Developments
11.4 Bayer AG
11.4.1 Bayer AG Company Information
11.4.2 Bayer AG Overview
11.4.3 Bayer AG Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Bayer AG Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bayer AG Recent Developments
11.5 BioLineRx, Ltd.
11.5.1 BioLineRx, Ltd. Company Information
11.5.2 BioLineRx, Ltd. Overview
11.5.3 BioLineRx, Ltd. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 BioLineRx, Ltd. Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 BioLineRx, Ltd. Recent Developments
11.6 BiOrion Technologies B.V.
11.6.1 BiOrion Technologies B.V. Company Information
11.6.2 BiOrion Technologies B.V. Overview
11.6.3 BiOrion Technologies B.V. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 BiOrion Technologies B.V. Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 BiOrion Technologies B.V. Recent Developments
11.7 Boehringer Ingelheim GmbH
11.7.1 Boehringer Ingelheim GmbH Company Information
11.7.2 Boehringer Ingelheim GmbH Overview
11.7.3 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Boehringer Ingelheim GmbH Recent Developments
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Information
11.8.2 Bristol-Myers Squibb Company Overview
11.8.3 Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bristol-Myers Squibb Company Recent Developments
11.9 Corbus pharmaceuticals, Inc.
11.9.1 Corbus pharmaceuticals, Inc. Company Information
11.9.2 Corbus pharmaceuticals, Inc. Overview
11.9.3 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Corbus pharmaceuticals, Inc. Recent Developments
11.10 CSL Limited
11.10.1 CSL Limited Company Information
11.10.2 CSL Limited Overview
11.10.3 CSL Limited Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 CSL Limited Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 CSL Limited Recent Developments
11.11 Daval International Limited
11.11.1 Daval International Limited Company Information
11.11.2 Daval International Limited Overview
11.11.3 Daval International Limited Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 Daval International Limited Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Daval International Limited Recent Developments
11.12 Digna Biotech, S.L.
11.12.1 Digna Biotech, S.L. Company Information
11.12.2 Digna Biotech, S.L. Overview
11.12.3 Digna Biotech, S.L. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Digna Biotech, S.L. Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Digna Biotech, S.L. Recent Developments
11.13 F. Hoffmann-La Roche Ltd.
11.13.1 F. Hoffmann-La Roche Ltd. Company Information
11.13.2 F. Hoffmann-La Roche Ltd. Overview
11.13.3 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.13.4 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 F. Hoffmann-La Roche Ltd. Recent Developments
11.14 Fibrocell Science, Inc.
11.14.1 Fibrocell Science, Inc. Company Information
11.14.2 Fibrocell Science, Inc. Overview
11.14.3 Fibrocell Science, Inc. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.14.4 Fibrocell Science, Inc. Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Fibrocell Science, Inc. Recent Developments
11.15 GenKyoTex S.A.
11.15.1 GenKyoTex S.A. Company Information
11.15.2 GenKyoTex S.A. Overview
11.15.3 GenKyoTex S.A. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.15.4 GenKyoTex S.A. Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 GenKyoTex S.A. Recent Developments
11.16 GlaxoSmithKline Plc
11.16.1 GlaxoSmithKline Plc Company Information
11.16.2 GlaxoSmithKline Plc Overview
11.16.3 GlaxoSmithKline Plc Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.16.4 GlaxoSmithKline Plc Systemic Sclerosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 GlaxoSmithKline Plc Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Systemic Sclerosis Drug Industry Chain Analysis
12.2 Systemic Sclerosis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Systemic Sclerosis Drug Production Mode & Process
12.4 Systemic Sclerosis Drug Sales and Marketing
12.4.1 Systemic Sclerosis Drug Sales Channels
12.4.2 Systemic Sclerosis Drug Distributors
12.5 Systemic Sclerosis Drug Customers
13 Market Dynamics
13.1 Systemic Sclerosis Drug Industry Trends
13.2 Systemic Sclerosis Drug Market Drivers
13.3 Systemic Sclerosis Drug Market Challenges
13.4 Systemic Sclerosis Drug Market Restraints
14 Key Findings in The Global Systemic Sclerosis Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Allergan Plc
Angion Biomedica Corp.
arGentis Pharmaceuticals, LLC
Bayer AG
BioLineRx, Ltd.
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Corbus pharmaceuticals, Inc.
CSL Limited
Daval International Limited
Digna Biotech, S.L.
F. Hoffmann-La Roche Ltd.
Fibrocell Science, Inc.
GenKyoTex S.A.
GlaxoSmithKline Plc
听
听
*If Applicable.